U.S. markets closed

Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
157.14+0.08 (+0.05%)
Al cierre: 04:00PM EDT
157.14 0.00 (0.00%)
Fuera de horario: 04:20PM EDT

Repligen Corporation

Building 1
Suite 100 41 Seyon Street
Waltham, MA 02453
United States
781 250 0111
https://www.repligen.com

Sector(es)Healthcare
IndustriaMedical Instruments & Supplies
Empleados a tiempo completo1,783

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Anthony J. HuntCEO & Director885kN/D1964
Mr. Olivier LoeillotPresident & Chief Commercial Officer1.49MN/D1970
Mr. James R. BylundChief Operating Officer472.18kN/D1964
Ms. Christine GebskiSenior Vice President of Filtration & Chromatography396.09kN/D1968
Mr. Ralf KuriyelSenior Vice President of Research & Development401.74kN/D1958
Mr. Keith Lee RobinsonChief Information OfficerN/DN/DN/D
Ms. Sondra S. NewmanGlobal Head of Investor RelationsN/DN/DN/D
Mr. Kola OtitojuSenior Vice President of Strategy & Business DevelopmentN/DN/DN/D
Dianne HeilerSenior Director of Packaging & SustainabilityN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Repligen Corporation a partir del 1 de abril de 2024 es 2. Las puntuaciones principales son Auditoría: 5; Junta: 3; Derechos del accionista: 1; Compensación: 4.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.